^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^Cosnier, D.; Duchene-Marullaz, P.; Grimal, J.; Rispat, G.; Streichenberger, G. (1975). „Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (Tolonidine), a new antihypertensive agent. I. Action on blood pressure and heart rate”. Arzneimittel-Forschung. 25 (10): 1557—1561. PMID1243037.
^Cosnier, D.; Labrid, C.; Rispat, G.; Streichenberger, G. (1975). „Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (tolonidine), a new antihypertensive agent. II. Action on cardiac contraction, circulatory parameters, autonomic receptors and diuresis”. Arzneimittel-Forschung. 25 (11): 1802—1806. PMID1243090.
^Cosnier, D.; Hache, J.; Labrid, C.; Streichenberger, G. (1975). „Pharmacological properties of 2-(2-chloro-p-toluidino)-2-imidazoline-nitrate (tolonidine), a new antihypertensive agent. III. Action on the secretions of the digestive tract and on the central nervous system, acute toxicity”. Arzneimittel-Forschung. 25 (12): 1926—1933. PMID3186.